Trial Profile
An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of RP6530, a Novel PI3K δ/γ Dual Inhibitor Given in Combination With an Anti-PD-1 Therapy, Pembrolizumab in Adult Patients With Relapsed or Refractory cHL
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tenalisib (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- Sponsors Rhizen Pharmaceuticals
- 24 Feb 2019 Status changed from recruiting to discontinued.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 29 May 2018 According to Rhizen Pharmaceuticals Meida release, data from this trial will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting